Drug intelligence / Profile preview

OPC-108459

Development stage: Discontinued
Lead developer: Otsuka Holdings
Modality: Small Molecules
Administration: Intravenous

Overview

OPC-108459 is an investigational intravenous small molecule antiarrhythmic drug that was developed by Otsuka Pharmaceutical for the rapid conversion of atrial fibrillation (AF) to sinus rhythm, specifically targeting paroxysmal and persistent forms of AF. The precise mechanism of action remains undefined, but it was intended as a novel agent within the antiarrhythmic class. Clinical development reached Phase 1 trials in multiple countries; however, further development was discontinued due to insufficient scientific evidence from early clinical studies[1][2][4][5].

Beyond the preview

Go deeper on OPC-108459.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPC-108459.

Explore the full profile